Compounds > (3S-5S-6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3-5-dihydroxyhept-6-enoic-acid

(3S-5S-6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3-5-dihydroxyhept-6-enoic-acid and Psoriasis

(3S-5S-6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3-5-dihydroxyhept-6-enoic-acid has been researched along with Psoriasis* in 1 studies

Other Studies

1 other study(ies) available for (3S-5S-6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3-5-dihydroxyhept-6-enoic-acid and Psoriasis

ArticleYear
Cyclosporin A pharmacokinetics in a patient with psoriasis and obesity, presenting with high levels of low-density [correction for destiny] lipoprotein.
    European journal of clinical pharmacology, 2002, Volume: 58, Issue:4

    Topics: Administration, Oral; Anticholesteremic Agents; Cyclosporine; Dermatologic Agents; Drug Synergism; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hyperlipoproteinemia Type II; Immunosuppressive Agents; Indoles; Lipoproteins, LDL; Middle Aged; Obesity; Psoriasis

2002